Abstract
Introduction
Inhaled corticosteroid (ICS) and long-acting β 2 -agonist (LABA) combinations are recommended as a Step 3 controller option in children aged 6-11 years in the Global Initiative for Asthma (GINA) guidelines, 1 where asthma is uncontrolled on ICS alone, although the preferred stepup therapy in this age group is medium-dose ICS.
Single-inhaler combination ICS/LABA therapy has been shown to increase treatment adherence and may improve treatment outcomes compared with free combinations of ICS and LABA as it assures concomitant administration of ICS. [2] [3] [4] To date, only two ICS/LABA combination therapies are available for use in children, namely fluticasone/salmeterol as both a dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI) (Seretide ® Accuhaler ® /Evohaler ® , respectively) and budesonide/formoterol DPI (Symbicort ® Turbohaler ® ).
Fluticasone propionate is an effective, well-established ICS, providing sustained anti-inflammatory effects. Formoterol fumarate is the most rapid-acting LABA, with a speed of onset comparable to the short-acting β 2 -agonist, salbutamol. Flutiform ® , fluticasone propionate and formoterol fumarate (fluticasone/formoterol) combination therapy via an HFA-propelled pMDI, has been evaluated in a number of studies in adults and/or adolescents with mild to severe asthma, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] and has been approved for use in this population in over 30 countries in Europe, Asia, and elsewhere. A single open-label study has also been conducted in pediatric asthmatic patients. 15 The present study (FFLAIR: Fluticasone propionate/FormoteroL Assessed In pediatric asthma) was designed to further evaluate the efficacy and safety of fluticasone/ formoterol in the pediatric population (EudraCT number: 2010-024635-16).
Methods

Participants
Male and female patients, aged 5 to <12 years, with persistent asthma for ⩾6 months, on a stable ICS dose for ⩾4 weeks, with predose forced expiratory volume in 1 s (FEV 1 ) ⩾ 60% to ⩽90% predicted, ⩾15% FEV 1 reversibility, and inadequate asthma control on an ICS alone at a dose of ⩽500 µg/day fluticasone (or equivalent) or controlled asthma on an ICS/LABA combination at an ICS dose of ⩽200 µg/day fluticasone (or equivalent), were eligible for enrolment.
Exclusion criteria were specified to ensure patient safety, for example, by excluding patients with potentially brittle asthma evidenced by life-threatening asthma within the past year, hospitalization or an emergency room visit for asthma within the past 6 months, systemic (injectable or oral) corticosteroid medication within 1 month and by excluding patients with current or prior nonresponse or partial response only to an ICS/LABA combination. Exclusion criteria were also specified to ensure disease stability at study entry, for example, by excluding patients with a clinically significant upper or lower respiratory infection within 4 weeks prior to study entry. Patients with coexistent pulmonary diseases (e.g. cystic fibrosis, bronchiectasis, tuberculosis) were also excluded.
Study design
This was a multicenter, randomized, double-blind, parallel-group study. Eligible patients entered a 14-day run-in period during which they received fluticasone pMDI (Flixotide ® Evohaler ® , GlaxoSmithKline, UK) 100 µg twice daily (b.i.d.). Salbutamol pMDI (Ventolin ® Evohaler ® , GlaxoSmithKline, UK) 100 µg was used as rescue medication. Patients completed an electronic diary daily to record rescue medication use, study medication use, asthma symptom scores, sleep disturbance due to asthma, and morning and evening peak flow (PEFR). The daytime and night-time symptom scales used are nonvalidated but have been employed in multiple prior studies. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Peak flow manoeuvres were performed in triplicate each morning and evening with the maximum value obtained used in subsequent analyses. Asthma symptoms were scored from 0 (no symptoms) to 5 (asthma so severe you cannot carry out normal daily activities). Sleep disturbance was scored from 0 (slept through the night, no asthma) to 4 (could not sleep at all due to asthma). An asthma control day was defined as a day with no asthma symptoms, no sleep disturbance due to asthma, and no rescue medication use. Mild to moderate asthma exacerbations were defined as at least 2 consecutive days with predose morning PEFR > 30% below baseline, and/or awakening due to asthma, and/or ⩾4 inhalations of rescue medication/day. Severe asthma exacerbations were defined as a deterioration in asthma requiring additional therapy (e.g. systemic corticosteroids) and/or The full analysis population (FAP) included all randomized patients who received at least one dose of study medication and had at least one valid efficacy (FEV 1 ) assessment. The per protocol population (PPP) included all patients in the FAP without major protocol violations.
The primary and key secondary endpoints were analyzed using a repeated measures approach based on observed data. For these endpoints, the primary comparison between fluticasone/formoterol and fluticasone was tested for superiority, based on the FAP. The secondary comparison (fluticasone/formoterol versus fluticasone/salmeterol) was tested for non-inferiority, based on the PPP. Non-inferiority was concluded if the lower limit of the 95% confidence interval (CI) for the least squares (LS) mean difference between treatments was ⩾−0.1 l. Supportive analyses for each comparison were performed using the alternative population. To account for missing data, sensitivity analyses were performed using multiple imputation methods.
The primary endpoint was tested in a hierarchical (gate keeping) manner. The test procedure started with the fluticasone/formoterol versus fluticasone comparison (evaluating superiority) and continued to the fluticasone/formoterol versus fluticasone/salmeterol comparison (evaluating non-inferiority) in a confirmatory manner, only if the first comparison (fluticasone/formoterol versus fluticasone) was significant at the 0.05 α level.
If both 2 h postdose FEV 1 comparisons were significant at the 0.05 α level (i.e. showed superiority compared with fluticasone and non-inferiority compared with fluticasone/salmeterol), only then were the key secondary endpoints (FEV 1 AUC at week 12 and change in predose FEV 1 over 12 weeks) tested in pairs using a Hochberg closedtesting procedure. The treatment comparisons were therefore ordered, such that if the comparison with the larger p value was not significant at α = 0.05, but the lower p value was significant at α = 0.025, the treatment comparison associated with the lower p value was considered statistically significant. Only if both treatment comparisons of the first pair of secondary endpoints (i.e. for FEV 1 AUC 0-4h ) were significant at the α = 0.05 level, would the next pair of secondary endpoints (i.e. for change in predose FEV 1 ) be tested in a confirmatory manner. Therefore, p values would be considered confirmatory if observed as statistically significant in the hierarchical testing strategy. If the confirmatory testing was stopped, subsequent endpoints in the hierarchy, as with the statistical tests of all other endpoints, would be considered exploratory.
The primary endpoint was analyzed using a repeatedmeasures analysis of covariance (ANCOVA) with fixed terms for treatment, age group, predose FEV 1 at baseline, visit and treatment by visit interaction, and center as a random effect. A similar model was employed to analyse the second key secondary endpoint (change in predose FEV 1 from baseline over 12 weeks). FEV 1 AUC 0-4 h at week 12 was analyzed using an ANCOVA with fixed terms for treatment, age group, predose FEV 1 at baseline, and center as a random effect.
For other efficacy endpoints, both treatment comparisons (fluticasone/formoterol versus fluticasone, Change from baseline in diary morning and evening predose PEFR, asthma symptom scores, sleep disturbance scores, percentage of symptom-free days, percentage of awakening-free nights, percentage of rescue-medication-free days, percentage of asthma-control days were analyzed using a similar repeated-measures ANCOVA as per the primary endpoint. The change in FeNO from baseline, PAQLQ and ACQ scores were analyzed using an ANCOVA as per FEV 1 AUC 0-4 h .
Post hoc analyses of the change from baseline in diary morning and evening predose FEV 1 over 12 weeks were performed using a similar repeatedmeasures ANCOVA as per the primary endpoint. Post hoc analyses of the change in clinic PEFR from predose at baseline to predose over the 12-week treatment period, and from predose at baseline to 2 h postdose over the 12-week treatment period were also performed using a similar ANCOVA to that employed for the primary endpoint analysis [but with predose PEFR (rather than FEV 1 ) at baseline as a fixed term].
The incidence of asthma exacerbations, the incidence of discontinuations due to lack of efficacy, the proportion of patients achieving a PAQLQ score increase ⩾ 0.5 units, and the proportion of patients achieving an ACQ score reduction ⩾ 0.5 units were analyzed using logistic regression. The annualized rate of asthma exacerbations was analyzed using a negative binomial model. The time to first asthma exacerbation was analyzed using a Cox proportional hazards model. The change in rescue medication puffs per day from baseline to each subsequent visit over the 12-week treatment period was analyzed using a repeated measures Friedman test. Other endpoints were summarized descriptively.
The analysis of safety data was based on the safety population, that is, all randomized patients who received at least one dose of study medication. Only descriptive summaries were generated.
Results
A total of 713 patients were screened and 512 randomized at 59 centers in 8 countries (Bulgaria, Czech Republic, Hungary, India, Poland, Romania, Russia and Ukraine). Of these, 481 patients (93.9%) completed the study. Slightly fewer patients discontinued in the fluticasone/formoterol group (8 patients) compared with the other treatment groups (fluticasone/salmeterol: 11; fluticasone: 12; Figure 2 ). Demographic and baseline asthma characteristics of all three treatment groups were similar (Table 1) . Other secondary endpoints Lung function. FVC, FEF 25 , FEF 50 , FEF 75 and FEF were summarized descriptively. Other than FVC, all these endpoints exhibited numerically greater predose and 2 h postdose changes from baseline with fluticasone/formoterol and fluticasone/salmeterol than with fluticasone monotherapy, with generally similar treatment effects observed with the two combination therapies (Table 2) .
Primary endpoint
Changes in clinic PEFR from predose at baseline to predose ( Figure 6 ) and 2 h postdose (Figure 7 ) over the 12-week treatment period were greater with fluticasone/formoterol and fluticasone/salmeterol than with fluticasone monotherapy, whilst effects with the combination therapies were similar to one another. the 5% level. Results for the change from baseline in daily predose evening PEFR over 12 weeks were similar: fluticasone/formoterol versus fluticasone LS mean difference 6.54 l/min [95% CI: 0.37, 12.71 l/min, p = 0.038 (FAP)]. Again, differences between fluticasone/salmeterol and fluticasone, and between the combination treatments were nonsignificant at the 5% level (Table S2) .
Symptoms. Substantial improvements in asthma symptom scores, the percentage of symptom-free days, sleep disturbance scores, the percentage of awakening-free nights, and the percentage of asthma control days were seen over the 12-week treatment period in all three treatment groups, with no between-group differences noted (Table 3) .
During the treatment period, a high proportion of patients (approximately 57%) across all treatment groups fulfilled the protocol definition of a mild/moderate asthma exacerbation, that is, at least 2 consecutive days with: asthma-related sleep Approximately 61% of patients across all treatment groups attained a clinically relevant improvement in health status (Table S3) .
Mean ACQ scores at baseline were high (approximately 1.9 units) in all treatment groups, and in all groups decreased (improved) by approximately 1.0 unit by week 12, with no significant between-group differences. Approximately 75% of patients across treatment groups attained a clinically relevant reduction in ACQ score by week 12 (Table S4) . AEs of bronchitis and upper limb fracture were both classified as serious AEs (that is, requiring hospitalization), whilst the severe laryngitis led to discontinuation from the study. None of these were considered related to study medication by the investigator. Overall analyses of AEs, laboratory parameters and vital signs did not reveal any safety concerns or notable differences in the safety of profile of the three study treatments.
Discussion
The primary endpoint (2 h postdose FEV 1 over 12 weeks) and first key secondary endpoint (FEV 1 AUC 0-4 at week 12) reflect both ICS and LABA treatment effects. 20 Fluticasone/formoterol was shown to be superior to fluticasone and non-inferior to fluticasone/salmeterol for both of these endpoints.
A 4 h serial spirometry was employed in this study on the basis of earlier fluticasone/formoterol studies in which FEV 1 AUC 0-4 h and FEV 1 AUC 0-12 h were shown to be highly correlated (Pearson correlation coefficient, R > 0.9). The 4 h endpoint compared with 12 h serial spirometry is also advantageous because it means an inpatient stay for 4 h rather than 12, which is far more Additionally, approximately half the number of forced expiratory manoeuvres are required to define a 4 versus 12 h profile, thereby reducing the potential for fatigue and noncompliance to confound the resultant data. Prior to study commencement, the use of the 4 h endpoint was discussed and agreed with the European Medicines Agency's Pediatric Committee.
The third endpoint in the testing hierarchy was predose FEV 1 over 12 weeks, which measures ICS effect 20 when LABA effects are at their lowest ebb over the dosing interval. Superiority of fluticasone/formoterol over fluticasone was not confirmed for this endpoint. However, for all closely analogous endpoints in the study (predose morning diary FEV 1 over 12 weeks; predose clinic PEFR over 12 weeks; predose morning diary PEFR over 12 weeks) significant differences between fluticasone/formoterol and fluticasone were noted. Whilst non-inferiority between fluticasone/formoterol and fluticasone/salmeterol was confirmed for predose FEV 1 over 12 weeks, per the prespecified non-inferiority margin of −0.1 l and Hochberg testing procedure, it should be acknowledged that this endpoint possessed limited assay sensitivity given the modest observed difference between fluticasone/formoterol and fluticasone. This limitation was indeed the reason for the a priori designation of the predose FEV 1 endpoint in the third tier of the confirmatory testing hierarchy.
Results for multiple other secondary lung function endpoints supported the results for the primary efficacy endpoint; lung function effects with fluticasone/formoterol and fluticasone/salmeterol were in almost all cases similar to one another and numerically greater than those observed with fluticasone, whether predose or postdose.
By contrast, results for the symptom-related and exacerbation endpoints were very similar across all three treatment arms. Changes from baseline for symptomatic indices were large. For the ACQ and PAQLQ, mean treatment changes from baseline considerably exceeded the threshold for the minimum clinically relevant within-individual change.
Unlike for adults, in whom the additional symptomatic benefits of ICS/LABAs are clear, this study showed differences between ICS/LABA compared with ICS alone for lung function but not for symptom-based outcomes. This is well described in the literature: the majority of pediatric studies of ICS/LABAs have reported a similar pattern. 2, [25] [26] [27] [28] The reason for the apparent difference in adult and pediatric populations may be the difficulties in obtaining a subjective assessment from young children, who do not possess a clear perception of time and whose recall of events is frequently not reliable. 29 Thus, events occurring shortly before clinical examination may be those most prominent to younger children. 30 In addition, younger children are less able to adequately verbalize their experiences, 30 whilst the perceived stigma associated with illness and a reluctance to differ from their healthy peers may result in under-reporting of symptoms. 29 Additionally, children subconsciously adapt their lifestyles to limit their symptom experience. 31 These factors may explain why reports of symptoms and activity limitation appear to be nonnormally distributed in asthmatic children (i.e. skewed towards being 'healthy/normal') 32 and differ from the symptomatic impairment reported by adults with the same objective degree of lung function impairment. 29 Such issues may also explain why parents underestimate the severity of their children's symptoms: Kuehni and Frey reported that almost 40% of parents reported their child's asthma control to be 'excellent' when in fact it was 'poor' per asthma guideline control criteria. 31 Such factors may similarly explain why symptomatic benefits are generally not seen in children with other GINA Step 3 options, that is, medium-dose ICS [32] [33] [34] [35] or ICS/leukotriene combinations, 36 when compared with low dose ICS.
It is less clear why, unlike in adults, ICS/LABAs do not appear to provide additional protection against severe exacerbations in children compared with ICS. It may be that severe events are also subject to the symptom-reporting issues described above, despite these events requiring therapeutic intervention, since the carer and physician must judge whether the child warrants review and then treatment. An alternative hypothesis is that stabilization of airway tone, a proposed mechanism by which LABAs reduce exacerbation risk, 37 may be relatively less important in children than in adults.
Results from the present study are nonetheless reassuring in that they provide no support for the view, based on earlier reports, that ICS/LABAs may be associated with an increased risk of severe exacerbations in children compared with ICS monotherapy. 38 In addition to the severe exacerbation data from the present 12-week study (no events in the fluticasone/formoterol group and two in each of the other arms), further reassurance is available from an earlier open-label, pediatric study of fluticasone/formoterol: 15 of the 208 asthmatic children treated with fluticasone/formoterol over 36 weeks, none experienced an exacerbation requiring systemic corticosteroids or hospitalization.
Our study did not assess growth, nor did it include a higher dose ICS monotherapy comparator. However, in view of current GINA guidelines advocating medium doses of ICS as the preferred GINA Step 3 therapy, the results of the CAMP study and two recent meta-analyses are relevant. In CAMP, an ICS dose-dependent reduction in final adult height of 0.1 cm/μg/kg body weight was seen (p = 0.007). 41 Similar findings were reported by Loke and colleagues 42 and Pruteanu and colleagues 43 in their respective meta-analyses. Although these growth impairment effects are relatively modest, they vary across children and warrant consideration when escalating ICS doses in pediatric patients.
Finally, the BADGER study offers perhaps the most useful recent insight into treatment escalation in pediatric asthma and the potential limitations of parallel-group designs in settings where individual patient responses vary considerably. In this double-blind, three-way crossover study, children uncontrolled on low-dose ICS were treated with three different step-up options [medium-dose ICS, add-on LABA, and add-on leukotriene receptor antagonist (LTRA)] in separate, 16-week study periods. 44 For all pairwise treatment comparisons, a substantial proportion of patients responded better to the 'less successful' treatment. Thus, whilst a greater proportion of patients responded better to LABA add-on (54%) than to ICS dose escalation (p = 0.002), a large minority of 32% responded better to the journals.sagepub.com/home/tar 13 latter. A very similar result was seen for the LABA versus LTRA comparison. The study model employed by Lemanske and coworkers thus illustrates the diversity of step-up responses in children, which may further contribute to the difficulty evidencing symptomatic treatment differences in this population. Similarly designed studies may represent a more informative model with which to evaluate asthma treatments in future pediatric studies.
Conclusion
Fluticasone/formoterol was superior to fluticasone and non-inferior to fluticasone/salmeterol in terms of effects upon lung function. All three treatments elicited large improvements in symptomatic indices, but no differences between treatments were evident for these outcomes, as in earlier ICS/LABA studies. Few severe exacerbations were seen in this 12-week study, with none observed on fluticasone/formoterol. Safety profiles were similar for all three study treatments. Overall, these results support the efficacy and safety of fluticasone/formoterol in children.
